Fangqin Xue

Prof. Dr. Fangqin Xue

Fujian Medical University, Fuzhou, Fujian, China
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2022 in Biomaterials
Verified
Journal Article
Closed access
PWPeiyuan Wang
Peiyuan Wang
JLJiaqi Li
Jiaqi Li
MWMin Wei
Min Wei
RYRuiqin Yang
Ruiqin Yang
KLKangliang Lou
Kangliang Lou
XLXiaolong Liu
Xiaolong Liu

1 June 2021 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
PWPeiyuan Wang
Peiyuan Wang
SJSuhua Jiang
Suhua Jiang
YLYang Li
Yang Li
QLQiang Luo
Qiang Luo
JLJinyan Lin
Jinyan Lin
Fangqin XueFangqin Xue
Fangqin Xue

11 July 2025 in International Journal of Biological Sciences
Verified
Journal Article
Open access
PDF file
QWQing Shui Wang
Qing Shui Wang
Fangqin XueFangqin Xue
Fangqin Xue
Yehuda G. AssarafYehuda G. Assaraf
Yehuda G. Assaraf
YLYao Lin
Yao Lin
Gastric cancer remains a major cause of mortality. The current standard of care of gastric cancer is based upon combination chemotherapy comprising platinum, fluoropyrimidines drugs and docetaxel. However, the efficacy of chemotherapy is hindered by intrinsic and acquired drug resistance, resulting in poor patient prognosis. Studies are currently exploring the potential of immunotherapy and other biologically targeted agents in the perioperative setting. To select the most efficacious therapy for advanced gastric cancer, including adenocarcinoma of the esophago-gastric junction, it is essential to determine key biomarkers including for example human epidermal growth factor receptor 2 (HER2) expression, programmed death-ligand 1 (PD-L1) combined positive score (CPS), Claudin 18.2, and microsatellite instability (MSI). Moreover, recent studies have highlighted the potential of natural products as effective agents in surmounting anticancer drug resistance in gastric cancer. These bioactive compounds exhibit various antitumor activities, including induction of apoptosis, inhibition of cell proliferation, modulation of autophagy, and most importantly reversal of distinct multidrug resistance (MDR) modalities. The present review provides a comprehensive analysis of the mechanisms underlying chemoresistance in gastric cancer and explores how natural products can overcome distinct MDR mechanisms. We further discuss the therapeutic potential of combining natural products with established chemotherapeutics and immunotherapy agents to enhance treatment efficacy and reduce adverse effects.

19 December 2024 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
MXMengjiao Xu
Mengjiao Xu
CXChao Xu
Chao Xu
YQYu Qiu
Yu Qiu
YFYushuo Feng
Yushuo Feng
QSQianqian Shi
Qianqian Shi
Fangqin XueFangqin Xue
Fangqin Xue
Radiotherapy and immunotherapy have already become the primary form of treatment for non-small-cell lung cancer (NSCLC), but are limited by high radiotherapy dose and low immune response rate. Herein, a multi-pronged strategy using a radio-immuno-enhancer (ZnO–Au@mSiO2) is developed by inducing tumor cells apoptosis and reprograming the immunosuppressive tumor microenvironment (TME). The radio-immuno-enhancer employed Au as a radiosensitizer, transition Zn ions as immune activators, which not only tremendously enhances the anti-proliferative activity of radiotherapy toward cancer cells, but also activates the immune response with multi-targets to let “exhausted” T cells “back to life” by triggering immunogenic cell death (ICD), immune checkpoint blockade (ICB) that target PD-1/PD-L1 and cGAS-STING under X-ray irradiation with a low dosage. The in vivo results demonstrate desirable antitumor and immunogenic effects of radio-immuno-enhancer-mediated immune activation by increasing the ratio of cytotoxic T cells (CTLs) and helper T cells. This work provides a feasible approach for future development of effective transition metal ion-activated radio-immunotherapeutic agents.

6 December 2022 in Talanta
Verified
Journal Article
Closed access
LCLiangjie Chi
Liangjie Chi
XWXiangyu Wang
Xiangyu Wang
HCHongyuan Chen
Hongyuan Chen
Dianping TangDianping Tang
Dianping Tang
Fangqin XueFangqin Xue
Fangqin Xue

17 May 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MHMingbin Huang
Mingbin Huang
CXChao Xu
Chao Xu
SYSen Yang
Sen Yang
ZZZiqian Zhang
Ziqian Zhang
ZWZuwu Wei
Zuwu Wei
Fangqin XueFangqin Xue
Fangqin Xue
Phototherapy, including photothermal therapy (PTT) and photodynamic therapy (PDT) has attracted growing attention as a noninvasive option for cancer treatment. At present, researchers have developed various “all-in-one” nanoplatforms for cancer imaging and PTT/PDT combinational therapy. However, the complex structure, tedious preparation procedures, overuse of extra carriers and severe side effects hinder their biomedical applications. In this work, we reported a nanoplatform (designated as ICG-MB) self-assembly from two different FDA-approved dyes of indocyanine green (ICG) and methylene blue (MB) without any additional excipients for cancer fluorescence imaging and combinational PTT/PDT. ICG-MB was found to exhibit good dispersion in the aqueous phase and improve the photostability and cellular uptake of free ICG and MB, thus exhibiting enhanced photothermal conversion and singlet oxygen (1O2) generation abilities to robustly ablate cancer cells under 808 nm and 670 nm laser irradiation. After intravenous injection, ICG-MB effectively accumulated at tumor sites with a near-infrared (NIR) fluorescence signal, which helped to delineate the targeted area for NIR laser-triggered phototoxicity. As a consequence, ICG-MB displayed a combinational PTT/PDT effect to potently inhibit tumor growth without causing any system toxicities in vivo. In conclusion, this minimalist, effective and biocompatible nanotheranostic would provide a promising candidate for cancer phototherapy based on current available dyes in clinic.